10-Q: Inotiv Reports Q1 2025 Results: Revenue Declines, Net Loss Widens Amid Strategic Realignment

Sentiment:

Quarterly Report 5 February 2025 9:20 PM

Inotiv's Q1 2025 results reveal a decrease in revenue and a widened net loss, driven by lower RMS segment performance, as the company focuses on strategic objectives including liquidity improvement and NHP revenue stabilization.

Capital raiseOn December 18, 2024, the Company entered into an underwriting agreement (the Underwriting Agreement) with Lake Street Capital Markets, LLC, as underwriter (the Underwriter), relating to the public offering of 6,000,000 common shares at a purchase price per share to the public of $4.25 (the Offering Price).Pursuant to the Underwriting Agreement, the Company granted the Underwriter a 30-day option to purchase up to an additional 900,000 common shares at the Offering Price, less underwriting discounts and commissions, which option was exercised in full and closed on December 30, 2024.Net proceeds from the offering were $27,524 after deducting the underwriting discounts and commissions and other offering expenses paid by the Company.

Worse than expectedThe company's revenue decreased by 11.5% compared to the same period last year.The company's consolidated net loss widened to $27.63 million, compared to a net loss of $15.83 million in the same period last year.

Summary

Inotiv's Q1 2025 revenue decreased by 11.5% to $119.88 million compared to $135.50 million in Q1 2024, primarily due to a decline in the Research Models and Services (RMS) segment.
The company's consolidated net loss widened to $27.63 million, or 23.0% of total revenue, compared to a net loss of $15.83 million, or 11.7% of total revenue, in the same period last year.
The Discovery and Safety Assessment (DSA) segment experienced a 4.2% revenue decrease, while the RMS segment saw a 15.1% decline, largely due to lower non-human primate (NHP) revenue.
The DSA services business achieved a book-to-bill ratio of 1.01x for the quarter.
DSA backlog was $130.39 million at December 31, 2024, compared to $129.92 million at September 30, 2024, and $152.30 million at December 31, 2023.
The company completed a public offering of common shares, generating net proceeds of $27.52 million to improve liquidity.
Inotiv is implementing a site optimization plan for its RMS business, expecting $4-5 million in annual cost savings upon completion by the end of fiscal 2026.
The company acknowledges substantial doubt about its ability to continue as a going concern, despite management's plans to improve operating results and optimize capital allocation.

Sentiment

Score: 4

Explanation: The sentiment is slightly negative due to declining revenue, widening net losses, and the acknowledged doubt about the company's ability to continue as a going concern. However, the successful equity offering and ongoing strategic initiatives provide some positive counterpoints.

Positives

The company successfully completed a public offering of common shares, generating net proceeds of $27.52 million, which will improve its liquidity position.
Inotiv is actively working to reduce NHP revenue volatility by expanding its client base and pre-selling inventory for calendar year 2025.
The company is integrating and improving its North American transportation and distribution systems, which is expected to improve client experience and operational efficiency.
The DSA services business achieved a book-to-bill ratio of 1.01x for the quarter, indicating a healthy demand for its services.
The company is implementing a site optimization plan for its RMS business, which is expected to result in $4-5 million in annual cost savings upon completion.

Negatives

Inotiv's Q1 2025 revenue decreased by 11.5% compared to the same period last year, primarily due to a decline in the RMS segment.
The company's consolidated net loss widened to $27.63 million, compared to a net loss of $15.83 million in the same period last year.
The RMS segment experienced a significant decrease in revenue due to lower NHP product and service revenue.
The company acknowledges substantial doubt about its ability to continue as a going concern.
The company's results of operations in the twelve months following the date of this report do not improve relative to the results of the first quarter of fiscal 2025, the Company will be at risk of non-compliance with its financial covenants under its Credit Agreement.

Risks

The company faces the risk of non-compliance with financial covenants under its Credit Agreement if its results of operations do not improve.
Failure to comply with financial covenants could lead to an event of default, potentially accelerating the repayment of outstanding debt.
The company's existing cash and cash equivalents, together with cash generated from operations, may not be sufficient to fund its operations and satisfy its obligations.
There is no assurance that the company's lenders will agree to any amendment to the Credit Agreement, or that the company will be able to raise additional capital.
The company's ability to continue as a going concern is subject to substantial doubt.
The company is subject to government investigations, inquiries and actions, including those described in Note 12.

Future Outlook

The company plans to optimize capital allocation, improve operating results through increased NHP revenue and DSA contract awards, and continue discussions with lenders. Management forecasts compliance with financial covenants under the Credit Agreement for the next twelve months, but there is no assurance that this plan will be successful.

Management Comments

During the three months ended December 31, 2024 , we moved forward with many of our strategic objectives which include improving the Companys liquidity position, reducing NHP revenue volatility, continuing to focus on client satisfaction and client relationships and continuing integration efforts.

Industry Context

The CRO industry is experiencing fluctuating demand, particularly in the NHP sector. Inotiv's focus on strategic realignment and cost optimization reflects a broader trend among CROs to adapt to changing market conditions and regulatory challenges.

Comparison to Industry Standards

It is difficult to compare Inotiv's results directly to industry standards without specific competitor data for Q1 2025.
However, companies like Charles River Laboratories and Envigo (prior to its acquisition) are key players in the CRO and research model sectors.
Charles River Laboratories reported revenue of $1.07 billion in Q4 2024, a 1.7% increase from $1.05 billion in Q4 2023.
Inotiv's revenue decline contrasts with the growth reported by Charles River Laboratories, indicating potential market share shifts or company-specific challenges.
The industry is also facing increased scrutiny regarding animal welfare and regulatory compliance, as evidenced by Inotiv's legal proceedings and government investigations.

Legal Proceedings

Envigo RMS, LLC (Envigo RMS) is a defendant in a purported class action and a related action under Californias Private Attorney General Act of 2004 (PAGA) brought by Jacob Greenwell, a former non-exempt employee of Envigo RMS, on June 25, 2021 in the Superior Court of California, Alameda County.
On June 23, 2022, a putative securities class action lawsuit was filed in the United States District Court for the Northern District of Indiana, naming the Company and Robert W. Leasure and Beth A. Taylor as defendants, captioned Grobler v. Inotiv, Inc., et al., Case No. 4:22-cv-00045 (N.D. Ind.).
On September 9, 2022, a purported shareholder derivative lawsuit was filed in the United States District Court for the Northern District of Indiana, naming Robert W. Leasure, Beth A. Taylor, Gregory C. Davis, R. Matthew Neff, Richard A. Johnson, John E. Sagartz, Nigel Brown, and Scott Cragg as defendants, and the Company as a nominal defendant, captioned Grobler v. Robert W. Leasure, et al., Case No. 4:22-cv-00064 (N.D. Ind.) (the Grobler Derivative Action).
On April 20, 2023, a purported shareholder derivative lawsuit was filed in the State of Indiana Tippecanoe County Circuit Court, naming Robert W. Leasure, Beth A. Taylor, Gregory C. Davis, R. Matthew Neff, Richard A. Johnson, John E. Sagartz, Nigel Brown, and Scott Cragg as defendants, and the Company as a nominal defendant, captioned Whitfield v. Gregory C. Davis, et al., Case No. 79C01-2304-PL-000048 (Tippecanoe Circuit Court) (the Whitfield Derivative Action).
On January 13, 2022, the Company filed a complaint against Freese and Nichols, Inc. ('FNI') titled Envigo RMS Holding Corp. and Envigo Global Services, Inc. v. Freese and Nichols, Inc., Case No. 22-01-61647-CV, in the District Court of Jim Wells County, Texas, 79th Judicial District related to, among other things, FNIs failure to design an adequately sized lagoon to dispose of the current wastewater and wastewater from expanded operations in the future.

Related Party Transactions

Seller Note Bolder BioPath (Related party) $ 320 $ 376
Seller Note Histion (Related party) 48 84

Stakeholder Impact

Shareholders: Dilution from equity offering, potential for further dilution if convertible notes are converted, uncertainty regarding future financial performance.
Employees: Potential for restructuring and site optimization to impact employment, focus on animal welfare and compliance.
Customers: Continued focus on client satisfaction and service improvements, potential for disruptions during site optimization.
Creditors: Risk of default if financial covenants are not met, potential for accelerated debt repayment.

Next Steps

Continue efforts to optimize capital allocation and expense base.
Improve operating results through increases to NHP-related product and service revenue.
Increase volume of discovery and safety assessment contract awards.
Continue discussions with lenders.
Implement and execute the site optimization plan for the RMS business.

Key Dates

Date	Description
November 5, 2021	Date of the Credit Agreement.
September 27, 2021	Date the Company issued $140,000 principal amount of the Notes.
January 7, 2022	The Company drew $35,000 on the Initial DDTL.
January 27, 2022	Date of the First Amendment to the Credit Agreement; the Company borrowed the full amount of the Incremental Term Loans.
January 27, 2022	Date of the acquisition of Orient BioResource Center, Inc. ('OBRC').
December 29, 2022	Date of the Second Amendment to the Credit Agreement.
January 9, 2023	Date of the Third Amendment to the Credit Agreement.
May 14, 2024	Date of the Fourth Amendment to the Credit Agreement.
June 2, 2024	Date of the Fifth Amendment to the Credit Agreement.
June 3, 2024	The Company announced that it had reached agreement with the U.S. Department of Justice ('DOJ') to resolve a previously-announced criminal investigation into its shuttered canine breeding facility located in Cumberland, Virginia.
August 7, 2024	Date of the Sixth Amendment to the Credit Agreement.
September 13, 2024	Date of the Seventh Amendment to the Credit Agreement; Date the Company and the Subsidiary Guarantors entered into a Purchase Agreement (the Purchase Agreement), dated September 13, 2024.
October 24, 2024	The Court sentenced Envigo RMS and EGSI according to the terms agreed to between the DOJ and the Company in the Resolution Agreement and Plea Agreement.
December 18, 2024	The Company entered into the Underwriting Agreement relating to the public offering of 6,000,000 common shares at a purchase price per share to the public of $4.25.
December 30, 2024	The Underwriter exercised in full and closed on December 30, 2024.
December 31, 2024	End of the reporting period.
January 20, 2025	On January 20, 2025, appoint the Compliance Monitor to review the Companys care of animals and compliance with certain laws.
February 5, 2025	Date of report.

Disclaimer:The information provided here is for general informational purposes only and does not constitute financial advice, recommendation, or endorsement of any kind. It may contain errors or omissions. You should not rely on this information to make financial decisions. Always seek the advice of a qualified financial professional before making any investment or financial decisions. Use of this information is at your own risk.